Q-omics provides the consensus-scored CCT5P1 profile across patient tissues and cancer cell-line models. CCT5P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCT5P1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CCT5P1 RNA expression shows 11,675 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where CCT5P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCT5P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCT5P1 survival associations across molecular data types. CCT5P1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCT5P1 RNA expression–survival associations across cancer types. High CCT5P1 expression shows unfavorable associations in KIRC, BRCA, LGG, LIHC and MESO, but favorable associations in LAML. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCT5P1 RNA expression.
This table summarizes CCT5P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCT5P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCT5P1 shows higher tumor expression in BLCA, LUAD, KIRC, HNSC, BRCA and COAD. The BLCA box plot shows higher CCT5P1 RNA expression in tumor versus normal tissue (log2 FC = +0.126, t-test p < 0.001).
This table shows molecular features associated with CCT5P1 in patient tissues and cancer cell lines. In patient samples, CCT5P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
